The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response ...

Diakonos Oncology has closed a $20m private placement of Simple Agreements for Future Equity (SAFE) for its Phase II trial of ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...

HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 ...

Scientists at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), in collaboration with national and ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel ...

This study reveals the potential of engineered phage-IL-12 therapy in melanoma, enhancing immune response and tumor ...

2025年6月6日-7日，第7届北京智源大会将以线上+线下联动的形式召开，本次智源大会汇聚四位图灵奖得主、海内外顶尖机构学者与产业领袖，在思辨与实证的交织中，为 AI 的未来绘制航图。报名通道已开启。2025北京智源大会倒计时：4 天NeuroAI: ...

Pulmonary fibrosis encompasses a spectrum of interstitial lung diseases (ILDs) characterized by chronic inflammation, aberrant tissue remodeling, and ...